Y-box结合蛋白1在慢性肝病发生发展中的作用

刘婷; 谢肖立; 姜慧卿

doi:10.3969/j.issn.1001-5256.2021.11.050

Y-box结合蛋白1在慢性肝病发生发展中的作用

DOI: 10.3969/j.issn.1001-5256.2021.11.050

河北医科大学第二医院消化内科，河北省消化病实验室，河北省消化病研究所，石家庄 050000

基金项目:

国家自然科学基金面上项目 (81770601);

河北省研究生创新资助项目 (CXZZBS2019121)

详细信息

通信作者:
姜慧卿，jianghq@aliyun.com

中图分类号: R575.2;R735.7
计量
- 文章访问数: 373
- HTML全文浏览量: 134
- PDF下载量: 17
- 被引次数: 0
出版历程
- 收稿日期: 2021-04-02
- 录用日期: 2021-04-22
- 出版日期: 2021-11-20

Role of Y-box binding protein-1 in the development and progression of chronic liver diseases

Department of Gastroenterology, The Second Hospital of Hebei Medical University; Hebei Key Laboratory of Gastroenterology; Hebei Institute of Gastroenterology, Shijiazhuang 050000, China

Research funding:

National Natural Science Foundation of China (81770601);

Post-graduate's Innovation Fund Project of Hebei Province (CXZZBS2019121)

摘要

摘要: 慢性肝病的病因多种多样，临床长期预后较差。Y-box结合蛋白1系一种多功能蛋白，近年来随着对其研究的深入，发现其在肝纤维化、肝细胞癌等慢性肝脏疾病的发生、发展等过程中均发挥着关键作用。总结了Y-box结合蛋白1在肝纤维化、肝细胞癌(增殖、凋亡、转移、疾病预后和耐药)及肝功能衰竭等慢性肝病中发挥的作用，为慢性肝病的诊治提供一定的理论依据。
- Y盒结合蛋白质1 /
- 肝硬化 /
- 肝细胞癌 /
- 肝功能衰竭
Abstract: Chronic liver diseases have various etiologies and often have poor long-term prognosis in clinical practice. Y-box binding protein-1 (YB-1) is a multifunctional protein, and in-depth studies in recent studies have found that it plays a key role in the development and progression of chronic liver diseases such as liver fibrosis and hepatocellular carcinoma (HCC). This article summarizes the role of YB-1 in chronic liver diseases such as liver fibrosis, HCC (proliferation, apoptosis, metastasis, prognosis, and drug resistance), and liver failure, so as to provide a theoretical basis for the diagnosis and treatment of chronic liver diseases.
- Y-Box-Binding Protein 1 /
- Liver Cirrhosis /
- Carcinoma, Hepatocellular /
- Liver Failure

HTML全文

图 1 YB-1结构域示意图

下载: 全尺寸图片幻灯片

参考文献(50)

[1]	MOHS A, OTTO T, SCHNEIDER KM, et al. Hepatocyte-specific NRF2 activation controls fibrogenesis and carcinogenesis in steatohepatitis[J]. J Hepatol, 2021, 74(3): 638-648. DOI: 10.1016/j.jhep.2020.09.037.
[2]	DAT NQ, THUY L, HIEU VN, et al. Hexa histidine-tagged recombinant human cytoglobin deactivates hepatic stellate cells and inhibits liver fibrosis by scavenging reactive oxygen species[J]. Hepatology, 2021, 73(6): 2527-2545. DOI: 10.1002/hep.31752.
[3]	BOYER-DIAZ Z, ARISTU-ZABALZA P, ANDRÉS-ROZAS M, et al. Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease[J]. J Hepatol, 2021, 74(5): 1188-1199. DOI: 10.1016/j.jhep.2020.11.045.
[4]	ELISEEVA IA, KIM ER, GURYANOV SG, et al. Y-box-binding protein 1 (YB-1) and its functions[J]. Biochemistry (Mosc), 2011, 76(13): 1402-1433. DOI: 10.1134/S0006297911130049.
[5]	MAURYA PK, MISHRA A, YADAV BS, et al. Role of Y Box Protein-1 in cancer: As potential biomarker and novel therapeutic target[J]. J Cancer, 2017, 8(10): 1900-1907. DOI: 10.7150/jca.17689.
[6]	KOHNO K, IZUMI H, UCHIUMI T, et al. The pleiotropic functions of the Y-box-binding protein, YB-1[J]. Bioessays, 2003, 25(7): 691-698. DOI: 10.1002/bies.10300.
[7]	ALEMASOVA EE, LAVRIK OI. At the interface of three nucleic acids: The role of RNA-binding proteins and poly(ADP-ribose) in DNA repair[J]. Acta Naturae, 2017, 9(2): 4-16.
[8]	YANSHINA DD, KOSSINOVA OA, GOPANENKO AV, et al. Structural features of the interaction of the 3'-untranslated region of mRNA containing exosomal RNA-specific motifs with YB-1, a potential mediator of mRNA sorting[J]. Biochimie, 2018, 144: 134-143. DOI: 10.1016/j.biochi.2017.11.007.
[9]	LIU H, XU D, CUI M, et al. The transcriptional factor YB-1 positively regulates Hsc70 transcription in Crassostrea hongkongensis[J]. Biochem Biophys Res Commun, 2018, 495(4): 2404-2409. DOI: 10.1016/j.bbrc.2017.12.110.
[10]	XIONG P, ZHANG J, XU D, et al. Positive feedback loop of YB-1 interacting with Smad2 promotes liver fibrosis[J]. Biochem Biophys Res Commun, 2017, 484(4): 753-761. DOI: 10.1016/j.bbrc.2017.01.148.
[11]	LYABIN DN, ELISEEVA IA, OVCHINNIKOV LP. YB-1 protein: Functions and regulation[J]. Wiley Interdiscip Rev RNA, 2014, 5(1): 95-110. DOI: 10.1002/wrna.1200.
[12]	YANG X, MA L, WEI R, et al. Twist1-induced miR-199a-3p promotes liver fibrosis by suppressing caveolin-2 and activating TGF-β pathway[J]. Signal Transduct Target Ther, 2020, 5(1): 75. DOI: 10.1038/s41392-020-0169-z.
[13]	INAGAKI Y, HIGASHIYAMA R, HIGASHI K. Novel anti-fibrotic modalities for liver fibrosis: Molecular targeting and regenerative medicine in fibrosis therapy[J]. J Gastroenterol Hepatol, 2012, 27(Suppl 2): 85-88. DOI: 10.1111/j.1440-1746.2011.07006.x.
[14]	HERMERT D, MARTIN IV, REISS LK, et al. The nucleic acid binding protein YB-1-controlled expression of CXCL-1 modulates kidney damage in liver fibrosis[J]. Kidney Int, 2020, 97(4): 741-752. DOI: 10.1016/j.kint.2019.10.024.
[15]	IMAI J, HOZUMI K, SUMIYOSHI H, et al. Anti-fibrotic effects of a novel small compound on the regulation of cytokine production in a mouse model of colorectal fibrosis[J]. Biochem Biophys Res Commun, 2015, 468(4): 554-560. DOI: 10.1016/j.bbrc.2015.10.123.
[16]	ZHOU LL, NI J, FENG WT, et al. High YBX1 expression indicates poor prognosis and promotes cell migration and invasion in nasopharyngeal carcinoma[J]. Exp Cell Res, 2017, 361(1): 126-134. DOI: 10.1016/j.yexcr.2017.10.009.
[17]	PANG T, LI M, ZHANG Y, et al. Y Box-binding protein 1 promotes epithelial-mesenchymal transition, invasion, and metastasis of cervical cancer via enhancing the expressions of snail[J]. Int J Gynecol Cancer, 2017, 27(8): 1753-1760. DOI: 10.1097/IGC.0000000000001066.
[18]	LIANG C, MA Y, YONG L, et al. Y-box binding protein-1 promotes tumorigenesis and progression via the epidermal growth factor receptor/AKT pathway in spinal chordoma[J]. Cancer Sci, 2019, 110(1): 166-179. DOI: 10.1111/cas.13875.
[19]	HSU C, LIN LI, CHENG YC, et al. Cyclin E1 inhibition can overcome sorafenib resistance in hepatocellular carcinoma cells through Mcl-1 suppression[J]. Clin Cancer Res, 2016, 22(10): 2555-2564. DOI: 10.1158/1078-0432.CCR-15-0499.
[20]	EN-NIA A, YILMAZ E, KLINGE U, et al. Transcription factor YB-1 mediates DNA polymerase alpha gene expression[J]. J Biol Chem, 2005, 280(9): 7702-7711. DOI: 10.1074/jbc.M413353200.
[21]	HARADA M, KOTAKE Y, OHHATA T, et al. YB-1 promotes transcription of cyclin D1 in human non-small-cell lung cancers[J]. Genes Cells, 2014, 19(6): 504-516. DOI: 10.1111/gtc.12150.
[22]	LIN Z, LU Y, MENG Q, et al. miR372 promotes progression of liver cancer cells by upregulating erbB-2 through enhancement of YB-1[J]. Mol Ther Nucleic Acids, 2018, 11: 494-507. DOI: 10.1016/j.omtn.2018.04.001.
[23]	FENG T, DZIERAN J, GU X, et al. Smad7 regulates compensatory hepatocyte proliferation in damaged mouse liver and positively relates to better clinical outcome in human hepatocellular carcinoma[J]. Clin Sci (Lond), 2015, 128(11): 761-774. DOI: 10.1042/CS20140606.
[24]	CHAO HM, HUANG HX, CHANG PH, et al. Y-box binding protein-1 promotes hepatocellular carcinoma-initiating cell progression and tumorigenesis via Wnt/β-catenin pathway[J]. Oncotarget, 2017, 8(2): 2604-2616. DOI: 10.18632/oncotarget.13733.
[25]	LI D, LIU X, ZHOU J, et al. Long noncoding RNA HULC modulates the phosphorylation of YB-1 through serving as a scaffold of extracellular signal-regulated kinase and YB-1 to enhance hepatocarcinogenesis[J]. Hepatology, 2017, 65(5): 1612-1627. DOI: 10.1002/hep.29010.
[26]	SHIMIZU S, TAKEHARA T, HIKITA H, et al. The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma[J]. J Hepatol, 2010, 52(5): 698-704. DOI: 10.1016/j.jhep.2009.12.024.
[27]	LASHAM A, LINDRIDGE E, RUDERT F, et al. Regulation of the human fas promoter by YB-1, Puralpha and AP-1 transcription factors[J]. Gene, 2000, 252(1-2): 1-13. DOI: 10.1016/s0378-1119(00)00220-1.
[28]	LUTZ M, WEMPE F, BAHR I, et al. Proteasomal degradation of the multifunctional regulator YB-1 is mediated by an F-Box protein induced during programmed cell death[J]. FEBS Lett, 2006, 580(16): 3921-3930. DOI: 10.1016/j.febslet.2006.06.023.
[29]	GUAY D, GAUDREAULT I, MASSIP L, et al. Formation of a nuclear complex containing the p53 tumor suppressor, YB-1, and the Werner syndrome gene product in cells treated with UV light[J]. Int J Biochem Cell Biol, 2006, 38(8): 1300-1313. DOI: 10.1016/j.biocel.2006.01.008.
[30]	LIU J, QU L, WAN C, et al. A novel β2-AR/YB-1/β-catenin axis mediates chronic stress-associated metastasis in hepatocellular carcinoma[J]. Oncogenesis, 2020, 9(9): 84. DOI: 10.1038/s41389-020-00268-w.
[31]	CHU PC, LIN PC, WU HY, et al. Mutant KRAS promotes liver metastasis of colorectal cancer, in part, by upregulating the MEK-Sp1-DNMT1-miR-137-YB-1-IGF-IR signaling pathway[J]. Oncogene, 2018, 37(25): 3440-3455. DOI: 10.1038/s41388-018-0222-3.
[32]	SETOGUCHI K, CUI L, HACHISUKA N, et al. Antisense oligonucleotides targeting Y-Box binding protein-1 inhibit tumor angiogenesis by downregulating Bcl-xL-VEGFR2/-Tie axes[J]. Mol Ther Nucleic Acids, 2017, 9: 170-181. DOI: 10.1016/j.omtn.2017.09.004.
[33]	GESSNER C, WOISCHWILL C, SCHUMACHER A, et al. Nuclear YB-1 expression as a negative prognostic marker in nonsmall cell lung cancer[J]. Eur Respir J, 2004, 23(1): 14-19. DOI: 10.1183/09031936.03.00033203.
[34]	WU Y, YAMADA S, IZUMI H, et al. Strong YB-1 expression is associated with liver metastasis progression and predicts shorter disease-free survival in advanced gastric cancer[J]. J Surg Oncol, 2012, 105(7): 724-730. DOI: 10.1002/jso.23030.
[35]	HA B, LEE EB, CUI J, et al. YB-1 overexpression promotes a TGF-β1-induced epithelial-mesenchymal transition via Akt activation[J]. Biochem Biophys Res Commun, 2015, 458(2): 347-351. DOI: 10.1016/j.bbrc.2015.01.114.
[36]	LOVETT DH, CHENG S, CAPE L, et al. YB-1 alters MT1-MMP trafficking and stimulates MCF-7 breast tumor invasion and metastasis[J]. Biochem Biophys Res Commun, 2010, 398(3): 482-488. DOI: 10.1016/j.bbrc.2010.06.104.
[37]	YASEN M, KAJINO K, KANO S, et al. The up-regulation of Y-box binding proteins (DNA binding protein A and Y-box binding protein-1) as prognostic markers of hepatocellular carcinoma[J]. Clin Cancer Res, 2005, 11(20): 7354-7361. DOI: 10.1158/1078-0432.CCR-05-1027.
[38]	ARDITO F, ARENA V, VELLONE M, et al. Strong YB-1 expression predicts liver recurrence following resection for colorectal metastases[J]. J Gastrointest Surg, 2014, 18(11): 1987-1993. DOI: 10.1007/s11605-014-2657-3.
[39]	PAGE AJ, COSGROVE DC, PHILOSOPHE B, et al. Hepatocellular carcinoma: Diagnosis, management, and prognosis[J]. Surg Oncol Clin N Am, 2014, 23(2): 289-311. DOI: 10.1016/j.soc.2013.10.006.
[40]	CUI Y, LI F, XIE Q, et al. YBX1 mediates autophagy by targeting p110β and decreasing the sensitivity to cisplatin in NSCLC[J]. Cell Death Dis, 2020, 11(6): 476. DOI: 10.1038/s41419-020-2555-4.
[41]	LIU S, CHEN L, ZHAO H, et al. Integrin β8 facilitates tumor growth and drug resistance through a Y-box binding protein 1-dependent signaling pathway in bladder cancer[J]. Cancer Sci, 2020, 111(7): 2423-2430. DOI: 10.1111/cas.14439.
[42]	LOU L, WANG J, LV F, et al. Y-box binding protein 1 (YB-1) promotes gefitinib resistance in lung adenocarcinoma cells by activating AKT signaling and epithelial-mesenchymal transition through targeting major vault protein (MVP)[J]. Cell Oncol (Dordr), 2021, 44(1): 109-133. DOI: 10.1007/s13402-020-00556-y.
[43]	TANAKA T, OHASHI S, SAITO H, et al. Indirubin 3'-oxime inhibits anticancer agent-induced YB-1 nuclear translocation in HepG2 human hepatocellular carcinoma cells[J]. Biochem Biophys Res Commun, 2018, 496(1): 7-11. DOI: 10.1016/j.bbrc.2017.12.106.
[44]	TANAKA T, SAITO H, MIYAIRI S, et al. 7-Hydorxyindirubin is capable of specifically inhibiting anticancer drug-induced YB-1 nuclear translocation without showing cytotoxicity in HepG2 hepatocellular carcinoma cells[J]. Biochem Biophys Res Commun, 2021, 544: 15-21. DOI: 10.1016/j.bbrc.2021.01.048.
[45]	WANG F, GONG S, WANG T, et al. Soyasaponin Ⅱ protects against acute liver failure through diminishing YB-1 phosphorylation and Nlrp3-inflammasome priming in mice[J]. Theranostics, 2020, 10(6): 2714-2726. DOI: 10.7150/thno.40128.
[46]	KULKARNI S, AUGOFF K, RIVERA L, et al. Increased expression levels of WAVE3 are associated with the progression and metastasis of triple negative breast cancer[J]. PLoS One, 2012, 7(8): e42895. DOI: 10.1371/journal.pone.0042895.
[47]	LI F, MA Z, LIU H, et al. Y-box protein-1 regulates the expression of collagen i in hepatic progenitor cells via PDGFR-β/ERK/p90RSK signalling[J]. Stem Cells Int, 2017, 2017: 6193106. DOI: 10.1155/2017/6193106.
[48]	MA Z, LI F, CHEN L, et al. Autophagy promotes hepatic differentiation of hepatic progenitor cells by regulating the Wnt/β-catenin signaling pathway[J]. J Mol Histol, 2019, 50(1): 75-90. DOI: 10.1007/s10735-018-9808-x.
[49]	TACKE F, KANIG N, EN-NIA A, et al. Y-box protein-1/p18 fragment identifies malignancies in patients with chronic liver disease[J]. BMC Cancer, 2011, 11: 185. DOI: 10.1186/1471-2407-11-185.
[50]	NGUYEN HH, SHAHEEN AA, BAEZA N, et al. Evaluation of classical and novel autoantibodies for the diagnosis of primary biliary cholangitis-autoimmune hepatitis overlap syndrome (PBC-AIH OS)[J]. PLoS One, 2018, 13(3): e0193960. DOI: 10.1371/journal.pone.0193960.